Karyopharm amends bylaws for universal proxy rules and meeting procedures

Karyopharm Therapeutics Inc.

Eliminated requirement to make stockholder list available during meetings.
Addressed adjournment of stockholder meetings due to technical failure in remote communication.
Enhanced disclosure and representation requirements for shareholder nominations under universal proxy rules.
Requires stockholders soliciting proxies to provide evidence of Rule 14a-19 compliance five business days before meeting.
Non-compliance with Rule 14a-19 will cause Company to disregard nominations and votes for those nominees.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Karyopharm Therapeutics Inc.: The Board approved and restated the Third Amended and Restated By-Laws, effective immediately, with amendments including elimination of stockholder list requirement during meetings, addressing remote meeting adjournment due to technical failure, and revising procedural mechanics for shareholder nomi (effective 2022-12-01).

Change: bylaw amendment
Effective: 2022-12-01

Exact text from the filing

On December 1, 2022, the board of directors (the “Board”) of Karyopharm Therapeutics Inc. (the “Company”) approved an amendment and restatement of the Company’s Second Amended and Restated By-Laws, as amended (as so amended and restated, the “Third Amended and Restated By-Laws”), effective immediately.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-297530

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.